Empagliflozin after Acute Myocardial Infarction (EMPACT-MI)
Source: View publication →
In patients at high risk for heart failure following an acute myocardial infarction, the addition of empagliflozin to standard of care did not significantly reduce the composite primary endpoint of first heart failure hospitalization or all-cause mortality.
Key Findings
Study Design
Study Limitations
Clinical Significance
While the primary composite endpoint was not met, the significant reduction in both first and recurrent heart failure hospitalizations suggests that SGLT2 inhibitors may provide mechanistic benefit in preventing heart failure progression in high-risk patients post-MI, independent of traditional diabetes or heart failure status, warranting careful consideration in clinical decision-making.
Historical Context
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated robust cardiovascular and renal benefits in patients with established heart failure and chronic kidney disease. EMPACT-MI was designed to investigate whether early initiation of this class could prevent the development of heart failure following an acute myocardial infarction, a period of high vulnerability for incident heart failure, following previous null or inconclusive results in similar post-MI trials like DAPA-MI.
Guided Discussion
High-yield insights from every perspective
SGLT2 inhibitors like empagliflozin are known for their 'metabolic' and 'hemodynamic' effects. In the context of an acute myocardial infarction (MI), which specific physiological mechanism is hypothesized to prevent the progression to heart failure, and why might this be independent of glucose-lowering effects?
Key Response
SGLT2 inhibitors promote osmotic diuresis and natriuresis, which reduces preload and ventricular wall tension. More importantly, they shift myocardial fuel metabolism from glucose to ketone bodies (which are more oxygen-efficient) and reduce myocardial sodium-hydrogen exchange. These mechanisms help mitigate adverse ventricular remodeling and sympathetic overactivity immediately following an ischemic injury, regardless of whether the patient has diabetes.
The EMPACT-MI trial enrolled patients with 'high-risk' myocardial infarction. Based on the study's inclusion criteria and outcomes, which specific clinical markers should a resident look for to identify patients who might still derive the most benefit from early SGLT2 inhibitor initiation, despite the neutral primary composite endpoint?
Key Response
While the primary composite endpoint was not significant, the trial showed a nominal reduction in heart failure hospitalizations (a 23% relative risk reduction). Residents should focus on patients with new-onset heart failure, a left ventricular ejection fraction <45%, or those requiring intravenous diuretics during the index admission, as these 'high-risk' features align with the population where the trend toward benefit was observed.
Compare the primary endpoint results of EMPACT-MI with the DAPA-MI trial. How do the differences in trial design (standard RCT vs. registry-based RCT) and endpoint selection (time-to-first-event vs. win-ratio) influence your interpretation of SGLT2 inhibitor efficacy in the post-MI setting?
Key Response
EMPACT-MI used a traditional time-to-first-event analysis for a hard composite (HFH or death) and was neutral (p=0.21). DAPA-MI used a 'win-ratio' for a broader cardiometabolic composite and was nominally 'positive' but did not show a reduction in hard clinical events like CV death. Together, they suggest that while SGLT2 inhibitors have clear benefits in chronic HF, their 'disease-modifying' effect on mortality immediately post-MI is less potent than established therapies like ACE inhibitors or Beta-blockers.
EMPACT-MI demonstrated a reduction in heart failure hospitalizations but no impact on all-cause mortality. In a value-based care model, does this evidence justify the routine addition of SGLT2 inhibitors to the standard 'post-MI cocktail' (DAPT, high-intensity statin, ACEi/ARB, Beta-blocker, MRA) during the index hospitalization?
Key Response
This is a point of clinical debate. The 'neutral' result for mortality makes it difficult to mandate SGLT2 inhibitors for every post-MI patient. However, reducing hospitalizations has significant quality-of-life and cost-saving implications. An attending should emphasize that while not 'practice-changing' for mortality, early initiation is safe and potentially beneficial for preventing the transition from 'at-risk' to 'clinical heart failure,' particularly in patients already having signs of congestion.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In EMPACT-MI, the primary endpoint was a composite of death or HF hospitalization. Discuss the statistical implications of the 'competing risk' of death and the 'dilution' effect of a neutral mortality component on a potentially sensitive morbidity component in a time-to-first-event analysis.
Key Response
In time-to-first-event models, if the drug has a strong effect on morbidity (HFH) but no effect on mortality, the composite hazard ratio is 'pulled' toward the null by the neutral mortality data. Furthermore, since patients who die cannot subsequently have an HF hospitalization, mortality acts as a competing risk. The PhD perspective would argue that a win-ratio or a joint model might have more accurately captured the benefit seen in the HFH component which was nominally significant when analyzed in isolation.
As a reviewer, if the authors of EMPACT-MI had emphasized the nominal p-value of 0.008 for heart failure hospitalization in the abstract despite the non-significant primary endpoint (p=0.21), what specific editorial concerns would you raise regarding 'multiplicity' and 'hierarchical testing'?
Key Response
A seasoned editor would flag this as 'cherry-picking.' Because the primary endpoint failed to reach statistical significance, according to the pre-specified hierarchical testing procedure, all subsequent p-values for secondary endpoints must be considered exploratory or hypothesis-generating only. Over-emphasizing a secondary benefit in the face of a neutral primary endpoint can lead to 'spin' and misrepresent the trial’s failure to meet its main objective.
Current AHA/ACC guidelines give a Class 1 recommendation for SGLT2 inhibitors in patients with HFrEF. Based on the EMPACT-MI results, is there sufficient evidence to elevate SGLT2 inhibitors to a Class 1 or 2a recommendation for the prevention of heart failure in post-MI patients without pre-existing HFrEF?
Key Response
The committee would likely maintain a conservative stance. Since EMPACT-MI failed its primary endpoint, a Class 1 recommendation for 'universal' post-MI use is unsupported. However, given the consistent signal for reduced HF hospitalizations across EMPACT-MI and DAPA-MI, a Class 2b (may be considered) recommendation might be appropriate for high-risk patients (e.g., LVEF <45% or congestion) to prevent HF progression, acknowledging the evidence is less robust than for established HFrEF.
Clinical Landscape
Noteworthy Related Trials
EMPA-REG OUTCOME
Tested
Empagliflozin
Population
T2DM patients with high cardiovascular risk
Comparator
Placebo
Endpoint
3-point MACE
EMPEROR-Reduced
Tested
Empagliflozin
Population
Patients with chronic heart failure and reduced ejection fraction
Comparator
Placebo
Endpoint
Cardiovascular death or hospitalization for heart failure
DAPA-MI
Tested
Dapagliflozin
Population
Patients with acute myocardial infarction
Comparator
Placebo
Endpoint
Hierarchical composite of death, hospitalization for heart failure, and other clinical events
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis